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TISSUEGENE-C (TG-C) IMPROVED CLINICAL SCORES IN PATIENTS
WITH OSTEOARTHRITIS: A PHASE 2B STUDY
B. Lee, J. Cho, T. Kim, Y. Park, E. Jeong, K.-H. Lee. Kolon Life Sci., Inc.,
Gwacheon-si, Republic of Korea
Purpose: TG-C is a cell mediated gene therapy that contains non-
transduced (hChonJ) and transduced (hChonJb#7) human allogeneic
chondrocytes. The hChonJb#7 cells were transduced with TGF-b1 gene
by using retroviral vector and irradiated with gamma-ray. TG-C has
been proved its efﬁcacy and safety in preclinical studies in vitro and in
vivo. TG-C has been tested in Phase I and Phase IIa clinical studies in
osteoarthritis (OA) patients and has proved its safety and efﬁcacy in the
patients.
Methods: The current placebo controlled phase IIb study was con-
ducted to determine both safety and efﬁcacy of TG-C in patients with OA
of the knee. Participants (n¼ 54) with a conﬁrmed diagnosis of knee OA
by X-ray and MRI were randomized into the treatment group (TG-C, 1.8
 107 cells/knee, n ¼ 27) and the placebo group (saline, n ¼ 27). The
primary evaluation parameter was International Knee Documentation
Committee (IKDC) which measures pain, sports activities, and daily
function. The secondary evaluation parameters were Western-Ontario
and MacMaster University (WOMAC) score, Knee Injury and Osteo-
arthritis Outcome Score (KOOS), and 100 mm Visual Analogue Scale
(VAS). These parameters were assessed at 12 and 24 weeks post
treatment. For TG-C treatment group, we also evaluated the all evalu-
ation parameters at 48 weeks post treatment. Additionally, changes in
biomarkers were assessed in serum and urine samples. Safety meas-
ures, including physical exams, complete blood count, and serum
chemistry were included up to 6 months post treatment. Blood samples
were screened to detect the replication competent retrovirus (RCR),
retrovirally transduced cells, and TGF-b1 DNA and protein starting from
2 weeks up to 6 months post treatment.
Results: TG-C treatmentgroup showed improvement in IKDC, WOMAC,
KOOS and 100 mm VAS scores compared toplacebo group as shown in
Table 1.Table 1
Changes in Scores of the Primary and the Secondary Evaluation Parameters at 24
weeks or 48 weeks post treatment, ITT set
TG-C(N ¼ 27) Placebo(N ¼ 27) P values
Primary
endpoint
IKDC, 24W 16.39  15.63 8.05  11.18 P ¼ 0.0304
IKDC, 48W 16.96  16.30 – P ¼ 0.00017
Secondary
endpoint
WOMAC, 24W 13.81  19.23 7.50  13.02 P ¼ 0.1692
WOMAC, 48 W 19.35  19.86 – P ¼ 0.00034
KOOS, 24W 22.96  27.15 13.92  16.85 P ¼ 0.1508
KOOS, 48W 29.15  29.31 – P ¼ 0.00028
VAS, 24W 24.83  27.29 10.79  18.22 P ¼ 0.0321
VAS, 48 W 33.35  29.10 – P ¼ 0.000021) Data for 48 weeks were TG-C treatment group.
2) The p value of 48 weeks were calculated with a comparison between
baseline to 48 weeks.
Conclusions: In summary, this Phase IIb study indicated that TG-C
treatment improved pain, sports activities, and quality of daily life in
patients with knee OA when compared to the placebo control.
334
RANDOMIZED, SINGLE CENTER, OBSERVER-BLIND, PARALLEL-
GROUP TRIAL TO EVALUATE THE SAFETY AND EFFECTIVENESS OF
HYADD4-G A VISCOELASTIC HYDROGEL, FOR THE TREATMENT OF
MENISCUS TEAR
C. Zorzi y, S. Rigotti y, N. Giordan z, V. Madonna y, V. Condello y,
F. Cortese y, V. Iacono y. yOrthopaedic and Traumatology Dept.,
Sacrocuore Negrar Hosp., Negrar (VR), Italy; z Fidia Farmaceutici S.p.A,
Abano Terme (PD), Italy
Purpose: Injury to themeniscus may play a key role in the development
of knee osteoarthritis (OA) and prior studies demonstrated that tear of
the meniscus are more common in patients with knee OA. Tears present
as severe pain, swelling and possible catching, difﬁculty on deep knee
bending and locking of the knee in partial ﬂexion. Basically, signs and
symptoms of meniscal tears are those of any OA disease where the
reduction of rheological properties of synovial ﬂuid of the affected jointincreases the susceptibility of the articular cartilage to damage. Clinical
trials have demonstrated the efﬁcacy of viscosupplementation in
patients undergoing arthroscopic partial meniscectomy with results on
pain reduction, better joint mobility and reduction of NSAIDs intake. On
this basis we aim to investigate whether intra-articular injections of
HYADD4-G (Hymovis) in patients with meniscal tears could improve
symptoms and knee functionality so to avoid arthroscopy surgery to the
patient.
Methods: This is a single site, randomised, parallel groups, observer-
blind, investigator initiated study. Upon signature of the informed
consent and satisfaction of all inclusion and exclusion criteria, each
patient was randomly assigned to control group, receiving only con-
servative treatment or to HYADD4-G group. Conservative treatment
consisted in use of an immobilizer brace, a combination of rest and ice,
knee off-loading and acetaminophen as per patient’s need. Patients
allocated to HYADD4-G group in addition to the conservative treat-
ment underwent to 2 injections of HYADD4-G two weeks apart: at
visit V1 (day 0) and at visit V2 (day 14). Pain was investigated through a
Visual Analogue Scale (VAS), knee pain stiffness and functionality
through the WOMAC questionnaire. Secondary objectives are the
evaluation of Quality of life by the SF-36 questionnaire, patient’s and
investigator’s global assessment of the disease (PTGA/COGA), intake of
analgesics and HYADD4-G safety. Meniscus tears were evaluated at
baseline and at the following visits by magnetic resonance imaging
scans. The study analyzed the relationship between the symptoms and
the presence of a meniscus tears.
Results: Fifty patients (25 in each of the two treatment groups) were
enrolled in the study. All patients receiving HYADD4-G in addition to
the conservative treatment completed the study, while only 17 out of
the 25 patients in the control group attended the visit 4 (day 60).
Reasons for discontinuing the study were lost to follow-up (4 patients),
surgery before visit 3 (3 patients) and treatment failure (1 patient). Pain
mean values decreases from 82.0 mm at baseline to 12.0 mm at V4 (day
60) in patients receiving HYADD4-G injection while in the control
group VAS pain decreases from 83.6 mm to 57.9 at V4 (day 60). Among
patients who completed the study a statistically signiﬁcant difference
was found between the groups at day 30 up to the end of the study at
day 60 (P < 0.001). Results obtained on pain were conﬁrmed by
WOMAC assessment. WOMAC pain sub-score, stiffness and function
showed the same trend. In particular considering WOMAC pain a stat-
istical signiﬁcant difference between two groups was found at day 30
and this difference persisted to day 60 (P < 0.001). No local or systemic
serious adverse events were observed during the study. Five patients
complained of local pain after injection. Four patients (3 included in
control group and 1 in HYADD4-G group) reported a worsening of the
baseline conditions; these events resulted in withdrawals from the
study.
Conclusion: Although it should be noted that the gold standard for the
evaluation of meniscus injuries is arthroscopic surgery, this study
demonstrates that patients who have been administered HYADD4-G
can improve their symptoms relief since 14 days after the ﬁrst treat-
ment and this decrease was maintained up to 60 days. Symptoms relief
together with MRI data are favourable to HYADD4-G study group,
suggesting a relationship of meniscus injury pain reduction and phys-
ical improvement in knee. In conclusion based on this study HYADD4-
G seems to be indicated for the treatment of pain in patients affected by
meniscal tear or degenerative signal but further investigations need to
be conducted on other symptoms related to this condition to conﬁrm
these promising data.
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TIBIAL SLOPE AND PATELLAR HEIGHT CHANGES FOLLOWING HIGH
TIBIAL OSTEOTOMY
W.S. Osman, M.G. Yousef, M.A. El Gebeily, R.G. Metwaly. Ain Shams
Univ., Cairo, Egypt
Objective: Improving the accuracy of high tibial osteotomy not only in
the coronal plane but with considering it as a three dimension proce-
dure can give better long term results in cases of medial compartment
osteoarthritis associated with varus deformity and minimize the
obstacles faced in future total knee replacement (TKR).
Design: Two different techniques of high tibial osteotomy: the opening
wedge (OWO) and the hemicallotasis osteotomy (HCO) were compared
clinically in a prospective randomized clinical trial that was held in Ain
Shams University hospitals in the period between December 2010 to
